Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstrating an inspiring complete remission rate. However, with extension of the follow-up period, the ...
HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities. Clin Transl Med. 2022;12(4):e791. Article PubMed PubMed Central Google Scholar Engelberts PJ, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and ...
NK92 cells expressing NK cell-specific CAR4, CAR7, and CAR9 had the greatest increase in anti-tumor activity when stimulated by mesohigh targets (Figures 1B–1E). These CARs also specifically enhanced CD107a expression (indicative of cytotoxic granule release) after meso+ target stimulation (...
We observed similar trends in the co-culture of NK-92 cells with HCT-116 cells, where the combination of 5 µM elraglusib and NK-92 cells showed increased tumor cell death as compared to the drug-only treatment or immune-cell-only treatment (Figure 1I). In the HT-29 cells, we ...
Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity. Antibodies 2015, 4, 426–440. [CrossRef] 35. Asano, R.; Sone, Y.; Makabe, K.; Tsumoto, K.; Hayashi, H.; Katayose, Y.; Unno, M.; Kudo, T.; ...